Intellia Q2 2026 Earnings: Lonvo-z Moves Toward a BLA

Intellia Therapeutics (Nasdaq: NTLA) reported Q2 2026 collaboration revenue of $7.7 million, down about 46% from $14.2 million a year earlier, while diluted net loss per share narrowed to $0.80 from $0.98. Net loss nevertheless widened to $106.6 million, while positive Phase 3 data moved lonvo-z closer to a planned biologics license application process.

Core Financial Results

Lower revenue from Regeneron and reduced other income outweighed a modest decline in total operating expenses. R&D spending fell as external costs for lead development programs and stock-based compensation declined, but G&A expenses rose with the buildout of Intellia’s commercial infrastructure, higher legal costs and increased stock-based compensation.

The operating loss widened because the $6.6 million decline in collaboration revenue was larger than the $3.8 million reduction in operating expenses. Lower other income also contributed to the increase in net loss.

Pipeline and Clinical Performance

Lonvo-z delivered positive Phase 3 HAE results

The Phase 3 HAELO trial of lonvoguran ziclumeran, or lonvo-z, met its primary endpoint and all key secondary endpoints. During the six-month efficacy evaluation period covering weeks 5 through 28, a one-time infusion reduced hereditary angioedema attacks by 87% versus placebo. The mean monthly attack rate was 0.26 for lonvo-z and 2.10 for placebo, with a p-value below 0.0001.

In addition, 62% of patients receiving lonvo-z were both attack-free and therapy-free during the evaluation period, compared with 11% in the placebo group. The monthly rates of attacks requiring on-demand treatment and moderate or severe attacks were also substantially lower in the treatment arm.

All treatment-emergent adverse events reported in the lonvo-z arm were mild or moderate, and no serious adverse events were observed in that arm. Intellia has also expanded launch preparations, including building field medical, reimbursement and strategic account teams and engaging with U.S. HAE treatment centers.

Nex-z enrollment resumed as Intellia evaluates an HLA finding

Intellia and Regeneron advanced enrollment in the MAGNITUDE and MAGNITUDE-2 Phase 3 trials of nexiguran ziclumeran, or nex-z, after enrollment was reinitiated during the quarter. The studies target ATTR amyloidosis with cardiomyopathy and hereditary ATTR amyloidosis with polyneuropathy, respectively.

A genomic analysis of more than 600 patient samples found that the highest observed liver transaminase elevations occurred in patients carrying a specific human leukocyte antigen allele. Intellia is discussing the finding with the FDA and other health authorities and plans to provide HLA genotyping results to investigators and patients enrolled in or entering screening for the ongoing Phase 3 trials. The finding adds a defined safety-monitoring issue even as enrollment proceeds.

The Equity Raise Extended the Runway While the Share Count Increased

Intellia ended June with $628.4 million in cash, cash equivalents and marketable securities, up from $605.1 million at the end of 2025. The company completed a public stock offering in April that generated approximately $195 million in net proceeds, strengthening the balance sheet as clinical development and commercial preparation continued.

Weighted-average diluted shares increased to 133.5 million from 103.7 million a year earlier, or approximately 29%. This larger denominator explains why the per-share loss narrowed even though the total net loss widened. Intellia expects its existing resources to fund operations at least into 2028, excluding any potential commercial revenue from lonvo-z.

Guidance and Key Milestones

Management maintained several time-based development, regulatory and liquidity targets. The planned commercial launch remains conditional on regulatory approval.

Recent Insider Transactions

The supplied insider data reports 401,906 shares under purchases across 14 transactions over the past six months, compared with 17,247 shares under sales across five transactions. That produced reported net purchases of 384,659 shares, but the aggregate data include different transaction types and should not be treated as evidence of insiders’ outlook.

The 10 most recent reported records consist of three officer sales in July 2026 and seven director stock awards in June.

Risks Investors Need to Watch

• Lonvo-z still faces regulatory risk: The expected BLA acceptance and planned first-half 2027 launch do not guarantee FDA approval or adherence to the current timeline.
• The nex-z HLA finding requires further evaluation: Intellia is engaging with regulators after linking the highest observed liver transaminase elevations to a specific HLA allele. The outcome could affect safety monitoring, enrollment or development requirements.
• Commercial spending is rising before product revenue begins: G&A expenses increased about 39% as Intellia expanded commercial infrastructure, while collaboration revenue declined about 46%.
• Ongoing losses continue to consume capital: The April offering strengthened liquidity and extended the stated runway, but it also came during a period in which the weighted-average share count rose materially.

Summary

Intellia’s Q2 2026 results were defined more by clinical and regulatory progress than by collaboration revenue. Lonvo-z produced positive Phase 3 HAE data and moved toward a potential BLA acceptance later in 2026, while nex-z enrollment resumed alongside new safety-related genomic analysis. The strengthened cash position provides funding into at least 2028, but investors still need to monitor regulatory execution, nex-z safety management, rising commercial costs and the effect of a larger share base.